Key Takeaways
- • PricewaterhouseCoopers has agreed to a $96 million settlement to resolve securities fraud litigation brought by Valeant Pharmaceuticals investors over alleged market manipulation schemes.
- • The settlement concludes a long-running class action lawsuit filed in New Jersey federal court, with the announcement made on September 10, 2026.
- • The litigation centered on Valeant (now part of Bausch), connecting PwC's audit and advisory role to investor losses stemming from the pharmaceutical company's accounting and disclosure practices.
- • This settlement represents a significant liability resolution for PwC and provides monetary recovery for affected securities holders in the investor class action.
Summary
PricewaterhouseCoopers LLP has agreed to pay $96 million to settle securities fraud claims brought by Valeant Pharmaceuticals investors, according to court filings in New Jersey federal court on September 10, 2026. The settlement resolves a class action lawsuit that alleged market manipulation by Valeant, the pharmaceutical company now operating as part of Bausch Health Companies.
The litigation targeted PwC's role in connection with Valeant's accounting practices and alleged securities violations. As one of the company's key professional service providers, PwC faced investor claims related to disclosure failures and market manipulation during Valeant's operational period. The settlement amount of $96 million reflects the resolution of these long-standing claims without an admission of liability from PwC.
This settlement carries significance for institutional investors who held Valeant securities during the period covered by the litigation, as it provides a recovery mechanism through the class action framework. The conclusion of this case removes ongoing legal exposure for PwC while delivering monetary compensation to the plaintiff class in New Jersey federal court.
The litigation targeted PwC's role in connection with Valeant's accounting practices and alleged securities violations. As one of the company's key professional service providers, PwC faced investor claims related to disclosure failures and market manipulation during Valeant's operational period. The settlement amount of $96 million reflects the resolution of these long-standing claims without an admission of liability from PwC.
This settlement carries significance for institutional investors who held Valeant securities during the period covered by the litigation, as it provides a recovery mechanism through the class action framework. The conclusion of this case removes ongoing legal exposure for PwC while delivering monetary compensation to the plaintiff class in New Jersey federal court.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.